Clinical Trial Update: Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin Resistance [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating pioglitazone added to pegylated interferon and ribavirin in chronic hepatitis C patients with insulin resistance has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Insulin Resistance

Drugs mentioned

• Actos (Pioglitazone)
• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis | Conditions: Chronic Hepatitis C, Insulin Resistance | Phase 3 | Status: TERMINATED